A (16:05)
Yeah, I'm very interested to hear how, like, how the public private partnership actually works here. There was a time when every, basically every cool technology was coming out of darpa, coming out of the US Government. The US Government landed on the moon. And since then, I think a lot of people in technology have lost faith in the US Government overseeing the development of technology, even academia. I mean, people think AGI will emerge from a private C Corp. That's where people believe that the best work will be done. Give Ilyas Sutzkever. Give the best scientist $3 billion. Let him go cook. That's the Currently, this feels like somewhat of a rejection of that in some ways. There's obviously lots of different places where having AI resources, having science and technology resources within the government make a ton of sense. But it'll be interesting to see, like, where are the interfacing points between the two. Between the two categories? By default, I think most people in our audience in technology would say, hey, let's leave the, let's leave the space travel and the AI research to the private sector. Should we run through The Astral Codex 10 piece on trait based embryo selection? This is from Scott Alexander in Astral Codex 10. He says suddenly, trait based embryo selection when a couple uses so in 2021, genomic prediction announced the first polygenically selected baby. When a couple uses IVF, they may get as many as 10 embryos. If they want one child, which one did they implant? In the early days, doctors would just eyeball them and choose whichever looked the healthiest. Later, they started testing for some of the most severe and easiest to detect genetic orders, like disorders like down syndrome and cystic fibrosis. The final step was polygenic selection, genotyping each embryo and implanting the one with the best genes overall. Best in what sense? Genomic prediction claimed the ability to forecast health outcomes from diabetes to schizophrenia. For example, although the average person has a 30% chance of getting type 2 diabetes, if you genetically test five embryos and select the one with the lowest predicted risk, they'll only have a 20% chance. So you get a 10% bump there. That's nice. Since you're taking the healthiest of many embryos, you should expect a child conceived via this method to be significantly healthier than one born naturally. Polygenic selection straddles the line between disease prevention and human enhancement. In 2023, Orchid Health, founded by Noor, who we've had on the show. Enter the field. Unlike Genomic Prediction, which tested only the most important genetic variants, Orcid offers whole genome sequencing, which can detect the de novo mutations involved in autism, developmental disorders and certain other genetic diseases. Critics accused GP and Orcid of offering designer babies, but this is only true in the weakest sense. Customers couldn't design a baby for anything other than slightly lower risk of genetic disease. You're basically just selecting out of what you already got. They're not editing the genes, they're merely sequencing them and then allowing you to select. These companies refused to offer selection on Traits, the industry term for the really controversial stuff like height, IQ or eye color. Still, these were trivial extensions of their technology. And everyone knew it was just a matter of time before someone took the plunge. Last month, a startup called Nucleus took the plunge. They had previously offered 23andMe style genetic tests for adults. Now they announced a partnership with Genomic Prediction for focusing on embryos. Although GP would continue to only test for health outcomes. You could forward the raw data from GP to Nucleus and Nucleus would predict extra traits including height, bmi, eye color, hair color, adhd, iq, and even handedness.